- Home
- DAWN vs LPTH Comparison
DAWN vs LPTH Comparison
Compare DAWN & LPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- LPTH
- Stock Information
- Founded
- DAWN 2018
- LPTH 1985
- Country
- DAWN United States
- LPTH United States
- Employees
- DAWN N/A
- LPTH N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- LPTH Semiconductors
- Sector
- DAWN Health Care
- LPTH Technology
- Exchange
- DAWN Nasdaq
- LPTH Nasdaq
- Market Cap
- DAWN 624.8M
- LPTH 377.5M
- IPO Year
- DAWN 2021
- LPTH 1996
- Fundamental
- Price
- DAWN $7.37
- LPTH $7.47
- Analyst Decision
- DAWN Strong Buy
- LPTH Strong Buy
- Analyst Count
- DAWN 7
- LPTH 3
- Target Price
- DAWN $27.86
- LPTH $6.83
- AVG Volume (30 Days)
- DAWN 1.3M
- LPTH 2.2M
- Earning Date
- DAWN 11-04-2025
- LPTH 11-13-2025
- Dividend Yield
- DAWN N/A
- LPTH N/A
- EPS Growth
- DAWN N/A
- LPTH N/A
- EPS
- DAWN N/A
- LPTH N/A
- Revenue
- DAWN $187,638,000.00
- LPTH $37,202,630.00
- Revenue This Year
- DAWN $12.88
- LPTH $62.13
- Revenue Next Year
- DAWN $48.27
- LPTH $22.15
- P/E Ratio
- DAWN N/A
- LPTH N/A
- Revenue Growth
- DAWN 2190.50
- LPTH 17.26
- 52 Week Low
- DAWN $5.64
- LPTH $1.40
- 52 Week High
- DAWN $16.76
- LPTH $10.69
- Technical
- Relative Strength Index (RSI)
- DAWN 51.95
- LPTH 46.56
- Support Level
- DAWN $6.90
- LPTH $7.84
- Resistance Level
- DAWN $7.62
- LPTH $9.03
- Average True Range (ATR)
- DAWN 0.37
- LPTH 0.85
- MACD
- DAWN -0.02
- LPTH -0.17
- Stochastic Oscillator
- DAWN 40.83
- LPTH 17.17
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About LPTH LightPath Technologies Inc.
LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.